Mol, Anuja Dokras, Kirsten McCaffery1: Polycystic ovary syndrome controversy: are expanding disease definitions unnecessarily labelling women with PCOS? British Medical Journal 358 : 2017.ĭokras A, Playford M, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Sarwer DB, Allison KC, Coutifaris C, Mehta N, Legro RS: Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome Clin Endocrinol 86 (50): 739-746,2017.ĭokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H: Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Fertil Steril : 2017. Tessa Copp1, Jesse Jansen1, Jenny Doust, Ben W. Fertility and Sterility 109 (5): 888-899,2018.Ĭopp T, Jansen J, Doust J, Mol BW, Dokras A, McCaffery K: Are expanding disease definitions unnecessarily labeling women with polycystic ovary syndrome? BMJ 358 : j3694,2017. : 2018.ĭokras A, Stener-Victorin E, Yildiz BO, Li R, Ottey S, Shah D, Epperson N, Teede H.: Androgen Excess-Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ International PCOS Network: Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Medical journal of Australia 209 Suppl 7 : S3-S8,2018.Ĭooney LG, Dokras A.: Beyond fertility: polycystic ovary syndrome and long-term health.ĭokras, Anuja: Improving care for women with polycystic ovary syndrome Fertil Steril 110 (1): 50-51,2018. Teede Helena J, Misso Marie L, Boyle Jacqueline A, Garad Rhonda M, McAllister Veryan, Downes Linda, Gibson-Helm Melanie, Hart Roger J, Rombauts Luk, Moran Lisa, Dokras Anuja, Laven Joop, Piltonen Terhi, Rodgers Raymond J, Thondan Mala, Costello Michael F, Norman Robert J: Translation and implementation of the Australian-led PCOS guideline: clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and sterility 112 (5): 930-938.e1,2019.Īlur-Gupta S, Dokras A.: Polycystic ovary syndrome: is the cardiometabolic risk increased after menopause?ĭokras A.: Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome? We are interested in understanding the impact of interventions such as lifestyle change, hormonal contraception, CBT on HRQOL, mood and anxiety disorders.Īlur-Gupta Snigdha, Chemerinski Anat, Liu Chang, Lipson Jenna, Allison Kelly, Sammel Mary D, Dokras Anuja: Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety. We were among the first groups to comprehensively demonstrate a fourfold increased risk of depression and anxiety in PCOS. Our second area of interest is to better understand the risk of lowered health related quality of life (HRQOL), and increased risk of anxiety and mood disorders in PCOS. Some of these studies are conducted in collaboration with Dr Dan Rader. We are currently interested in understanding the determinants of CVD risk by performing studies at both cellular level (lipid phenotyping, HDL function) and population levels (impact of steroid hormones on lipids, studying role of androgens in subclinical atherosclerosis). Our studies have shown that young women with PCOS have an increased risk of obesity, dyslipidemia, metabolic syndrome and subclinical atherosclerosis compared to age matched controls. Both cardiovascular disease (CVD) and mood disorders are associated with significantly physical and emotional morbidity and add significantly to the financial burden of the healthcare system. Our research program has two main interests understanding long term cardiovascular morbidity and risk of depression and anxiety disorders in PCOS. It is associated with significant gynecological, dermatologic, metabolic and psychiatric co-morbidities. Keywords: PCOS, androgens, metabolic risk, mood disorders, HRQOL Research Details:PCOS is the commonest endocrine disorder in reproductive age women with a prevalence of 8-15%. Research Interests: Dr Dokras directs the Penn Polycystic Ovary Syndrome (PCOS) trans disciplinary research program. Premature Menopause (Premature Ovarian Insufficiency)
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |